Source Count: 14 | Weighted Score: 33 | Source Confidence: [4/5] | Primary Tier: 1–2 | Last Updated: March 9, 2026
Keywords: cannabis, marijuana, hemp, THC, CBD, endocannabinoid system, anandamide, 2-AG, CB1, CB2, Raphael Mechoulam, psychoactive, Scythians, Herodotus, bhang, ganja, hashish, Cannabis sativa, Cannabis indica, terpenes, entourage effect, medical cannabis, Schedule I, dagga, charas, Rastafari, altered states, anxiolytic, psychosis risk
Category Tags: altered states, pharmacology, ethnobotany, history, neuroscience, medicine
Cross-References: Y_1_01 — Altered States Psychedelics · Y_1_05 — Soma Haoma · Y_1_02 — Ergot Sacred Pharmacology · X_1_01 — Medicine Overview · C_2_01 — Global Traditions Overview

QUICK SUMMARY

Cannabis (Cannabis sativa L.) is one of humanity's oldest cultivated plants, with a relationship spanning at least 12,000 years based on archaeological evidence. Its use as fiber (hemp), food (seeds), medicine, and psychoactive sacrament is documented across cultures from Central Asia to Africa, India, China, and the pre-modern Middle East. The primary psychoactive compound, delta-9-tetrahydrocannabinol (THC), was first isolated by Raphael Mechoulam and Yechiel Gaoni at the Hebrew University of Jerusalem in 1964. This discovery eventually led to the identification of the endocannabinoid system (ECS) — an endogenous neurotransmitter system involving the cannabinoid receptors CB1 (concentrated in the brain — hippocampus, basal ganglia, cerebellum, cortex) and CB2 (primarily in immune cells), the endogenous ligands anandamide (discovered by Mechoulam's group in 1992, named from the Sanskrit ānanda, "bliss") and 2-arachidonoylglycerol (2-AG), and the enzymes that synthesize and degrade them. The ECS modulates pain perception, appetite, mood, memory, immune function, and neuroplasticity — making it one of the most important neuromodulatory systems in the body. Historical use: the earliest archaeological evidence comes from the Oki site in Japanese Jōmon culture (~10,000 BCE, hemp fiber) and the Yanghai tombs in Xinjiang, China (~2,500 BCE, cannabis likely for psychoactive use — Russo et al., 2008). Herodotus (c. 440 BCE) described Scythians inhaling cannabis smoke in enclosed tents after funerals — a practice confirmed by archaeological finds of cannabis residue in braziers at Scythian burial sites (Ren et al., 2019, Science Advances). In India, cannabis (bhang, ganja, charas) has been sacred to Shiva for millennia, used in religious festivals (Holi, Shivaratri) and described in the Atharvaveda (c. 1500–1000 BCE) as one of five sacred plants. In the Islamic world, hashish use spread from the 10th century CE onward despite prohibition; the "Assassins" legend (medieval Ismaili Nizari sect) falsely attributed their motivation to hashish use. African traditions use cannabis (dagga, riamba) in spiritual and healing contexts. Modern research has clarified both therapeutic potential (chronic pain, epilepsy [epidiolex/CBD], chemotherapy-induced nausea, multiple sclerosis spasticity) and risks (psychosis risk with heavy adolescent use, cannabis use disorder, impaired driving and cognition during acute intoxication).

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Scholarly Consensus)

1.1 Pharmacology: THC, the Endocannabinoid System

• THC isolation: Mechoulam and Gaoni (1964, Journal of the American Chemical Society) isolated and synthesized delta-9-THC from Lebanese hashish — identifying it as the primary psychoactive constituent
• CB1 receptor: cloned by Matsuda et al. (1990) — the most abundant G-protein-coupled receptor in the brain; concentrated in hippocampus (memory), basal ganglia (movement), cerebellum (coordination), cortex (cognition), amygdala (emotion)
• Anandamide: discovered by Devane et al. (1992, Science) — an endogenous lipid neurotransmitter that binds CB1; rapidly degraded by fatty acid amide hydrolase (FAAH)
• 2-AG: the most abundant endocannabinoid, acting as a full agonist at CB1 and CB2; involved in retrograde signaling — endocannabinoids are released by postsynaptic neurons and travel backward to inhibit presynaptic neurotransmitter release, functioning as a "brake" on excessive neural activity
• Effects of THC: partial agonist at CB1 → euphoria, altered time perception, enhanced sensory experience, appetite stimulation, impaired short-term memory, anxiolysis at low doses/anxiety at high doses; effects on creativity and perception make it distinct from classical psychedelics (which act primarily on serotonin 5-HT2A)
• CBD (cannabidiol): non-psychoactive (no CB1 agonist activity); acts through multiple mechanisms including 5-HT1A agonism, TRPV1 activation, and modulation of anandamide breakdown; FDA-approved as Epidiolex for Dravet syndrome and Lennox-Gastaut syndrome (severe childhood epilepsies)

1.2 Archaeological and Historical Evidence

• Yanghai tombs, Xinjiang (c. 2,500 BCE): large quantity of cannabis was found in a shaman's grave — analysis confirmed high THC content, suggesting psychoactive (not merely fiber) use (Russo et al., 2008, Journal of Experimental Botany)
• Jirzankal Cemetery, Pamir Mountains (c. 500 BCE): Ren et al. (2019, Science Advances) found cannabis residue with elevated THC in wooden braziers at a burial site — the earliest chemical evidence of cannabis smoking for psychoactive purposes, aligning with Herodotus' account of Scythian practices
• Herodotus (Histories 4.73–75, c. 440 BCE): described Scythians throwing cannabis seeds on heated stones inside felt tents, "howling with pleasure" from the smoke — once considered possibly exaggerated, now confirmed by archaeological chemistry
• Indian textual tradition: the Atharvaveda (~1500–1000 BCE) lists cannabis among five sacred plants; bhang (ground cannabis leaves in milk/yogurt) is consumed during Hindu festivals; Sufi traditions in South Asia incorporated cannabis for contemplative purposes
• Chinese pharmacopoeia: Shennong Bencaojing (c. 1st century CE) lists cannabis (ma) for pain, malaria, rheumatism, and other conditions; cannabis was used medicinally in China for at least 2,000 years while recreational/psychoactive use was less documented than in South Asia

1.3 Medical Cannabis: Evidence Base

• Chronic pain: systematic reviews (Whiting et al., 2015, JAMA; National Academies, 2017) find moderate-quality evidence for cannabinoid treatment of chronic pain, with effect sizes comparable to or smaller than conventional analgesics
• Chemotherapy-induced nausea: nabilone and dronabinol (synthetic THC) are FDA-approved; moderate-quality evidence supports efficacy
• Epilepsy (CBD): high-quality RCT evidence for CBD (Epidiolex) in Dravet and Lennox-Gastaut syndromes (Devinsky et al., 2017, New England Journal of Medicine)
• Multiple sclerosis spasticity: nabiximols (Sativex, THC:CBD spray) approved in >25 countries for MS spasticity; moderate evidence of efficacy

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Risks: Psychosis, Adolescent Use, Dependence

• Cannabis and psychosis: epidemiological evidence (Di Forti et al., 2019, The Lancet Psychiatry) shows that daily use of high-potency cannabis is associated with a 5-fold increased risk of psychotic disorder; the relationship appears dose-dependent and is strongest for individuals with genetic vulnerability (COMT Val158Met polymorphism); debate continues about whether cannabis causes psychosis or triggers it in predisposed individuals
• Adolescent brain development: heavy cannabis use during adolescence is associated with cognitive deficits (attention, memory, executive function) and structural brain changes (Meier et al., 2012, PNAS; though the Meier findings were challenged by Rogeberg, 2013, who argued confounding by socioeconomic factors); the developing brain may be particularly vulnerable because the ECS plays a role in neural pruning and maturation
• Cannabis use disorder: ~9% of those who try cannabis develop dependence (Anthony et al., 1994, Experimental and Clinical Psychopharmacology); withdrawal symptoms (irritability, insomnia, appetite loss, anxiety) are mild relative to alcohol or opioids but clinically significant

2.2 Ethnobotanical Traditions

• African cannabis traditions: cannabis reached sub-Saharan Africa by at least the 13th–14th century CE (possibly earlier); used as dagga by Khoisan peoples, in water pipes (riamba) by Central African groups, and in spiritual/healing contexts by Zulu and other peoples (Du Toit, 1980)
• Rastafari: cannabis (ganja, "the holy herb") became central to Rastafari spiritual practice in Jamaica (1930s onward) — used in reasoning sessions for meditation, scriptural study, and communion with Jah; Rastafari cite Genesis 1:29 and Revelation 22:2 as biblical authorization; the sacramental use of cannabis in this context is a modern development, not an ancient tradition
• The "Assassins" legend: the claim that the medieval Nizari Ismaili sect's members (the Hashīshīyyīn) were motivated or controlled by hashish administration is widely regarded as propaganda by their Sunni enemies — Farhad Daftary (The Assassin Legends, 1994) demonstrated that the "hashish" etymology is uncertain and the intoxication narrative has no support in Nizari sources

2.3 The Entourage Effect

• The "entourage effect" hypothesis (Ben-Shabat et al., 1998; Russo, 2011): proposes that cannabis's effects are shaped by the interaction of multiple compounds — THC, CBD, other cannabinoids (CBN, CBG, THCV), terpenes (myrcene, limonene, linalool), and flavonoids — rather than by THC alone
• Some evidence supports this: CBD modulates THC's psychoactive effects (potentially reducing anxiety); certain terpenes have independent anxiolytic or anti-inflammatory properties
• However, the entourage effect is more widely promoted commercially than scientifically validated — rigorous clinical evidence for specific synergies between minor cannabinoids and terpenes is limited (Cogan, 2020)

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Cannabis in Ancient Religious Traditions

• Kan-bosm / qaneh-bosem: Benet (1975) proposed that the Hebrew qaneh-bosem (an ingredient in the holy anointing oil — Exodus 30:23) was cannabis rather than sweet calamus; this hypothesis is accepted by scholars but remains debated — the identification is linguistically possible but not confirmed
• Zoroastrian mang/bhang: the Avestan mang and its possible connection to cannabis (bhang) in Zoroastrian ritual is debated; cannabis may have been an ingredient in or substitute for the sacred Haoma preparation (see Y_1_05)
• The broader question of whether cannabis played a more widespread role in ancient Mediterranean and Near Eastern religion than currently recognized is plausible but requires more archaeological and chemical evidence

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Cannabis Is Completely Harmless

• DEBUNKED The claim that cannabis has no negative health effects is not supported — while cannabis is less acutely dangerous than many substances (no confirmed lethal dose in humans from THC alone), it carries real risks: psychosis risk with heavy high-potency use, dependence in ~9% of users, cognitive impairment during adolescent use, impaired driving, and respiratory issues from smoking (National Academies, 2017)

IMAGES

No images assigned yet.

Counter-Arguments & Criticisms

No significant counter-arguments exist in the scholarly literature for the core claims presented here. The topic of Cannabis History Ethnobotany Pharmacology represents established knowledge within altered states of consciousness with no active scholarly dispute over the fundamental claims presented in this document.

BIBLIOGRAPHY

1. Mechoulam, R.; Gaoni, Y | 1965 | "A Total Synthesis of dl-Δ1-Tetrahydrocannabinol" | Journal of the American Chemical Society | ∅ | 87::3273–3275 | ∅ | ∅ | doi:10.1021/ja01092a065 | ∅ | ∅ | ∅
2. Devane, W.A. et al | 1992 | "Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor" | Science | ∅ | 258::1946–1949 | ∅ | ∅ | doi:10.1126/science.1470919 | ∅ | ∅ | ∅
3. Russo, E.B. et al | 2008 | "Phytochemical and Genetic Analyses of Ancient Cannabis from Central Asia" | Journal of Experimental Botany | ∅ | 59::4171–4182 | ∅ | ∅ | doi:10.1093/jxb/ern260 | ∅ | ∅ | ∅
4. Ren, M. et al. eaaw1391 | 2019 | "The Origins of Cannabis Smoking: Chemical Residue Evidence from the First Millennium BCE in the Pamirs" | Science Advances | ∅ | 5:: | ∅ | ∅ | doi:10.1126/sciadv.aaw1391 | ∅ | ∅ | ∅
5. Di Forti, M. et al | 2019 | "The Contribution of Cannabis Use to Variation in the Incidence of Psychotic Disorder Across Europe" | The Lancet Psychiatry | ∅ | 6::427–436 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
6. Devinsky, O. et al | 2017 | "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome" | New England Journal of Medicine | ∅ | 376::2011–2020 | ∅ | ∅ | doi:10.1056/nejmoa1611618 | ∅ | ∅ | ∅
7. National Academies of Sciences, Engineering; Medicine | 2017 | ∅ | The Health Effects of Cannabis and Cannabinoids | ∅ | ∅ | National Academies Press | ∅ | ∅ | ∅ | ∅ | ∅
8. Whiting, P.F. et al | 2015 | "Cannabinoids for Medical Use: A Systematic Review and Meta-analysis" | JAMA | ∅ | 313::2456–2473 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Russo, E.B | 2011 | "Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects" | British Journal of Pharmacology | ∅ | 163::1344–1364 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Daftary, F | 1994 | ∅ | The Assassin Legends: Myths of the Isma'ilis | ∅ | ∅ | I.B | ∅ | ∅ | ∅ | ∅ | Tauris
11. Du Toit, B | 1980 | ∅ | Cannabis in Africa | ∅ | ∅ | Balkema | ∅ | ∅ | ∅ | ∅ | ∅
12. Meier, M.H. et al | 2012 | "Persistent Cannabis Users Show Neuropsychological Decline" | Proceedings of the National Academy of Sciences | ∅ | 109:: | E2657 E2664 | ∅ | ∅ | ∅ | ∅ | ∅
13. Anthony, J.C. et al | 1994 | "Comparative Epidemiology of Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants" | Experimental and Clinical Psychopharmacology | ∅ | 2::244–268 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Matsuda, L.A. et al | 1990 | "Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA" | Nature | ∅ | 346::561–564 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Last Updated: March 9, 2026